Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:00 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors
NCT06024174 · Bristol-Myers Squibb · PHASE1/PHASE2 · terminated · last registry update 2025-07-22 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Business objectives have changed” | – | Registry record, Bristol-Myers Squibb |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against KRAS within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-07-22Results posted on the registry: Amgen, Sotorasib + Panitumumab (NCT05198934)
- 2026-07-13Results posted on the registry: Amgen, Sotorasib (NCT04933695)
- 2026-07-13Also stopped (terminated): Amgen, Sotorasib (NCT04933695)
- 2026-04-22Also stopped (terminated): Ningbo Newbay Technology Development Co., Ltd, NB004 tablets (NCT05036291)
- 2026-04-09Also stopped (terminated): M.D. Anderson Cancer Center, Adagrasib + Olaparib (NCT06130254)
- 2026-04-08Also stopped (terminated): Deciphera Pharmaceuticals, LLC, Inlexisertib + Trametinib (NCT04892017)
- 2026-02-19Also stopped (terminated): Mirati Therapeutics Inc., MRTX0902 + MRTX849 (NCT05578092)
- 2026-01-06Results posted on the registry: Revolution Medicines, Inc., RMC-4630 + Sotorasib (NCT05054725)
- 2025-12-16Results posted on the registry: Medical University of South Carolina, Sotorasib and Tarloxotinib + Sotorasib and Tarloxotinib (NCT05313009)
- 2025-12-16Also stopped (terminated): Medical University of South Carolina, Sotorasib and Tarloxotinib + Sotorasib and Tarloxotinib (NCT05313009)
- 2025-09-15Also stopped (withdrawn): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Adagrasib + Adagrasib/Nivolumab (NCT05472623)
- 2025-07-25Also stopped (withdrawn): M.D. Anderson Cancer Center, MRTX849 (NCT05634525)
- 2025-05-29Also stopped (terminated): Sanofi, Vociprotafib + Pembrolizumab (NCT04418661)
- 2025-05-01Results posted on the registry: Vitrac Therapeutics, LLC, VIC-1911 + sotorasib (NCT05374538)
- 2025-05-01Also stopped (terminated): Vitrac Therapeutics, LLC, VIC-1911 + sotorasib (NCT05374538)
- 2025-04-25Also stopped (terminated): Mirati Therapeutics Inc., Adagrasib + nab-Sirolimus (NCT05840510)
- 2025-04-20Results posted on the registry: Sanofi, Vociprotafib + Pembrolizumab (NCT04418661)
- 2025-03-13Phase 3 first posted: Mirati Therapeutics Inc., Adagrasib + Pembrolizumab (NCT06875310)
- 2025-01-22Results posted on the registry: Mirati Therapeutics Inc., MRTX849 + Docetaxel (NCT04685135)
- 2024-12-16Also stopped (terminated): Mirati Therapeutics Inc., MRTX849 + BI 1701963 (NCT04975256)
- 2024-12-12Also stopped (terminated): Navire Pharma Inc., a BridgeBio company, BBP-398 + sotorasib (NCT05480865)
- 2024-11-20Also stopped (withdrawn): ETOP IBCSG Partners Foundation, Sotorasib + Lenvatinib (NCT06068153)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision